Panthera Biopartners Secures Major Investment from LDC to Expand UK's Largest Clinical Trial SMO Network
核心洞察
Panthera Biopartners (搜索), the UK's largest Site Management Organisation for commercial clinical trials, has secured investment from private equity firm LDC (搜索) to accelerate expansion plans.
The company achieved remarkable growth with revenue increasing by more than 200% since 2022, while serving eight of the 12 largest pharmaceutical companies.
In 2024, Panthera was the top global recruiter in four international clinical studies and had the first patient recruited in nine trials globally or within the UK.
Panthera Biopartners (搜索), the UK's largest Site Management Organisation (SMO) for commercial clinical trials, has secured a significant investment from leading private equity investor LDC (搜索) to support its expansion plans and further enhance its clinical capabilities. The transaction marks a successful exit for BGF (搜索) and Gresham House Ventures (搜索), with BGF reinvesting as a minority shareholder alongside LDC.
Rapid Growth and Market Leadership
Since its establishment in 2019 by co-founders Dr Ian Smith and Professor John Lyon, Panthera has demonstrated exceptional growth trajectory. The company achieved rapid expansion following BGF (搜索) and Gresham House Ventures (搜索)' investment in 2022, with revenue increasing by more than 200%. This remarkable performance has positioned Panthera as a dominant force in the clinical trials sector.
Headquartered in Preston, Lancashire, the company operates six UK sites with two more planned and provides clinical trials for eight of the 12 largest pharmaceutical companies and all of the largest seven clinical research organisations (CROs). In 2024, Panthera was the top global recruiter in four international clinical studies and had the first patient recruited in nine trials globally or within the UK.
Comprehensive Clinical Trial Capabilities
Panthera specialises in the recruitment of patients and running of Phase II and Phase III clinical trials. Its service offering spans trial planning, data collection and patient retention across a broad spectrum of therapeutic areas including vaccines (搜索), cardiovascular medicine (搜索), diabetes (搜索), neurology (搜索), respiratory medicine (搜索), dermatology (搜索), rheumatology (搜索) and early dementia (搜索) trials.
The company has built an outstanding market reputation due to its ability to recruit patients at speed and provide sponsors with certainty around study delivery, streamlining the route to commercialisation. Access to a large number of Principal Investigators (PIs) across the site network enables the business to service studies across diverse therapeutic areas. In the last quarter of 2024 alone, Panthera signed up more than 1,000 UK patients to take part in its studies.
Strategic Investment and Leadership
LDC (搜索) is backing the existing management team, led by CEO Stuart Young, CCO Chris Dodd, CFO Rory Lloyd, CMO Dr. Mahadev Ramjee and CIO Andy Broomhead. Dr Ian Smith will continue to advise the company. The investment was led by LDC's North West team, including Partner and Head of North West Dale Alderson, Investment Director Grant Goodwin and Investment Manager Alex Kirkby, who will join Panthera's board as Non-Executive Directors alongside Mark Egerton as Chairman.
Stuart Young, CEO of Panthera, commented: "We're incredibly proud of what the team at Panthera has achieved and are excited to partner with LDC (搜索) for this next phase of growth. Their investment will help us accelerate expansion, enhance our capabilities, and continue delivering for our clients and patients. With LDC's support and experience, we look forward to broadening our reach into Europe and expanding access to clinical trials across new regions."
Expansion Plans and Market Opportunity
With LDC (搜索)'s support, Panthera will seek to further expand its operations in the UK and Europe, increase its number of clinical sites, invest in technology, and scale its trial delivery capabilities. As SMOs continue to play an increasingly pivotal role in the drug development value chain, significant growth opportunities exist in the sector.
Grant Goodwin, Investment Director at LDC (搜索), added: "Patient recruitment and dropout rates have historically been one of the biggest hurdles to efficient clinical trial processes and it's this challenge that Panthera has proven it can solve. Stuart and his excellent team have built a trusted operation with well-established client relationships. We're looking forward to supporting them as they pursue their growth strategy."
LDC's Healthcare Investment Track Record
In the last decade alone, LDC (搜索) has invested more than £409m into 18 healthcare companies with a combined enterprise value of £920m. Its experience of helping management teams in the sector to grow their business extends right across the UK and includes Synexus (搜索) (another clinical trial SMO), which it helped diversify and expand to the US and Europe, diagnostic imaging equipment provider Medray Group and Bullen Healthcare, the UK's largest independent dispensing appliance contractor of stoma, urology and wound care products. In June 2025, LDC was named Private Equity Investor of the Year at the annual HealthInvestor Awards in recognition of its support for the sector.